Adaptive Trial Design

Almac’s suite of technologies and biostatistical services seamlessly implement and support adaptive trial design. Well-designed adaptive trials result in lower drug development costs, reduced time to market, faster go-no-go-decisions, and improved patient safety.

Our IXRS® and ePRO tools capture safety and efficacy data and make it viewable in real-time, so that sponsors have the information to take action as predetermined in the protocol. The flexibility of IXRS® facilitates making changes (e.g., dropping or adding treatment arms, changing doses,) during the course of a trial.

Almac has experience in implementing over 100 adaptive studies and has established the reputation as a market leader in the area.

Flash replacement image